The role of minimal residual disease testing in myeloma treatment selection and drug development: Current value and future applications

Kenneth C. Anderson, Daniel Auclair, Gary J. Kelloff, Caroline C. Sigman, Hervé Avet-Loiseau, Ann T. Farrell, Nicole J. Gormley, Shaji K. Kumar, Ola Landgren, Nikhil C. Munshi, Michele Cavo, Faith E. Davies, Alessandra Di Bacco, Jennifer S. Dickey, Steven I. Gutman, Howard R. Higley, Mohamad A. Hussein, J. Milburn Jessup, Ilan R. Kirsch, Richard F. LittleRobert D. Loberg, Jens G. Lohr, Lata Mukundan, James L. Omel, Trevor J. Pugh, Gregory H. Reaman, Michael D. Robbins, A. Kate Sasser, Nancy Valente, Elena Zamagni

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Fingerprint

Dive into the research topics of 'The role of minimal residual disease testing in myeloma treatment selection and drug development: Current value and future applications'. Together they form a unique fingerprint.

Medicine & Life Sciences